BMJ Best Practice

参考文献

关键文献

Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med. 2003;142:385-390.

Nazer H, Ede RJ, Mowat AP, et al. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27:1377-1381.

Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston, MA: Kluwer Academic Publishers, 2001.

Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, ed. Major problems in internal medicine. Vol 23. Philadelphia, PA: WB Saunders, 1984:1-171.

Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.

Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521-527.

参考文章

1.  Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327-337.

2.  Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344-350.

3.  Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun. 1993;197:271-277.

4.  Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med. 2003;142:385-390.

5.  Nazer H, Ede RJ, Mowat AP, et al. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27:1377-1381.

6.  Starosta-Rubinstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilson's disease: correlations with structural changes on magnetic resonance imaging. Arch Neurol. 1987;44:365-370.

7.  Brewer GJ. Behavioral abnormalities in Wilson's disease. In: Weiner WJ, Lang AE, Anderson KE, eds. Behavioral neurology of movement disorders. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2005:262-274.

8.  Dedoussis GV, Genschel J, Sialvera TE, et al. Wilson disease: high prevalence in a mountainous area of Crete. Ann Hum Genet. 2005;69:268-274.

9.  Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston, MA: Kluwer Academic Publishers, 2001.

10.  Hoogenraad TU. Wilson's disease. London, UK: Saunders, 1996.

11.  Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, ed. Major problems in internal medicine. Vol 23. Philadelphia, PA: WB Saunders, 1984:1-171.

12.  Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41:668-670.

13.  Cox DW, Roberts E. Wilson disease. Seattle: GeneClinics, University of Washington; 2006.

14.  Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine Baltimore. 1992;71:139-164.

15.  Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr. 1993;12:527-530.

16.  Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med. 2000;223:39-46.

17.  Brewer GJ. Wilson's disease. In: Kasper DL, Braunward E, Fauci AS, et al, eds. Harrison's principles of internal medicine. 16th ed. New York, NY: McGraw-Hill Companies, 2004:2313-2315.

18.  Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Exp Opin Pharmacother. 2006;7:317-324.

19.  Merle U, Eisenbach C, Weiss KH, et al. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol. 2009;51:925-930.

20.  McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol. 2009;131:160-165.

21.  Hedera P. Update on the clinical management of Wilson's disease. Appl Clin Genet. 2017 Jan 13;10:9-19.

22.  Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089-2111.

23.  Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11:441-448.

24.  Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1:643-647.

25.  Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.

26.  Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-495.

27.  Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol. 1987;44:490-493.

28.  Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521-527.

29.  Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379-385.

使用此内容应接受我们的免责声明